Our message at the CBD Expo, simplified, was “Labskin is the science for CBD product compliance!”. Labskin will offer CBD brands verifiable scientific data that backs up product claims without the cost of hiring a full-time microbiologist and major capital investment in a microbiology laboratory.
September has been a busy month for the Labskin team! Fresh off the plane from San Diego, USA, where we attended the Microbiome Movement Conference on skin health & dermatology to present on advances in our AI technology, we went to Birmingham, UK to take part in the 2nd Hemp & CBD Expo. Labskin presented on product claims and regulation for CBD companies and brands entering the European market. Paul Ryan, Chief Business Development Officer, and David Caballero-Lima, Services Manager, attended the weekend expo.
Day One – Saturday 14.9.19
The first day featured meetings with CBD manufacturers looking to bring CBD-infused cosmetic and skincare products to market. CBD, or Cannabidiol, is legally permitted in the UK and Europe once it adheres to the legal requirements (i.e. THC (Tetrahydrocannabinol) levels are less than 0.2%). CBD derived from the marijuana flower or bud remains classified as an illegal substance in most EU countries, while CBD derived from stems, leaves or seeds is permitted under EU law for use in skincare and cosmetic products.
Testing these products and substantiating claims is becoming a priority now for many of the CBD companies Labskin spoke with over the weekend. New regulations (for example Rule 21 of EU MDR 2017/745) specify that all products that are absorbed into the skin are now classified as a Medical Device and face strict clinical testing and proof of efficacy. So planned CBD products will require evidence of compliance.